Biogen (BIIB) Asset Writedowns and Impairment (2009 - 2026)

Biogen (BIIB) has reported Asset Writedowns and Impairment for 11 consecutive years, with $4.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Asset Writedowns and Impairment fell 34.25% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $61.2 million (up 53.0% YoY), while the FY2025 annual figure was $29.2 million, down 51.5% from the prior year.
• Asset Writedowns and Impairment came in at $4.8 million for Q1 2026 at Biogen, down from $52.9 million in the prior quarter.
• The five-year high for Asset Writedowns and Impairment was $275.0 million in Q1 2022, with the low at -$62.1 million in Q4 2023.
• Average Asset Writedowns and Impairment over 5 years is $69.5 million, with a median of $19.8 million recorded in 2023.
• Across the five-year window, Asset Writedowns and Impairment surged 2210.92% in 2022 and slumped 122.58% in 2023, its largest moves.
• Year by year, Asset Writedowns and Impairment stood at $275.0 million in 2022, then tumbled by 122.58% to -$62.1 million in 2023, then surged by 120.13% to $12.5 million in 2024, then jumped by 323.2% to $52.9 million in 2025, then plunged by 90.93% to $4.8 million in 2026.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $4.8 million, $52.9 million, and $3.5 million for Q1 2026, Q4 2025, and Q2 2025 respectively.